ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,474.90
      0.96%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. PhaseBio Pharmaceuticals Inc (PHAS)

      7. PhaseBio Pharmaceuticals Inc (PHAS) News

      PHAS

      PhaseBio Pharmaceuticals (PHAS)

      PhaseBio Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:PHAS
      DateTimeSourceHeadlineSymbolCompany
      02/14/20224:21PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      02/10/20228:00AMBusiness WirePhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific SessionNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      02/04/20229:31AMEdgar (US Regulatory)Schedule 13gNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      02/01/20222:42PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      01/14/20225:05PMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      12/21/202112:55PMTipRanksNeedham Thinks Phasebio Pharmaceuticals’ Stock is Going to RecoverNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      12/21/20218:04AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      12/21/20218:00AMBusiness WirePhaseBio Provides Pemziviptadil (PB1046) Program UpdateNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      12/01/20215:01PMBusiness WirePhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM EvidenceNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/23/20216:55PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/23/20216:54PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/23/20216:53PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/23/20216:52PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/23/20216:50PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/18/20214:01PMBusiness WirePhaseBio Names Jonathan Birchall as Chief Commercial OfficerNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/15/202111:33AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/15/202111:31AMBusiness WirePhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening BleedingNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/12/20214:11PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/10/20214:42PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/10/20214:00PMBusiness WirePhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business HighlightsNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/10/20218:01AMBusiness WirePhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual MeetingNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/03/20217:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/03/20217:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/03/20218:05AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      11/03/20218:00AMBusiness WirePhaseBio Announces Topline Results From Phase 2b Trial for BentracimabNASDAQ:PHASPhaseBio Pharmaceuticals Inc
      10/06/20218:00AMBusiness WirePhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      09/15/20218:17AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      09/15/20218:17AMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      09/15/20218:07AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
      09/15/20218:00AMBusiness WirePhaseBio Appoints William D. Humphries to Board of DirectorsNASDAQ:PHASPhaseBio Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:PHAS